Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Analysis, Demand And Outlook 2025- 2034

 For those planning market entry or expansion, this report lays out critical data and expert analysis on the alpha-1 antitrypsin deficiency augmentation therapy industry landscape.

What Is The Projected Market Size & Growth Rate Of The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.

The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp

What Is The Crucial Factor Driving The Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
An increase in the number of respiratory diseases is driving the growth of the alpha-1 antitrypsin deficiency augmentation therapy market. Respiratory diseases are disorders that affect the lungs and the respiratory system, leading to breathing difficulties and impaired lung function. Alpha-1 antitrypsin deficiency augmentation therapy aims to treat respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. The therapy works by restoring the balance of protease-antiprotease activity in the lungs, protecting lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health organization, in the United States, 8,300 tuberculosis (TB) cases were reported in 2022, a rise from 7,874 cases in 2021. Therefore, the increase in the number of respiratory diseases propels the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Segment Covered In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report
The alpha-1 antitrypsin deficiency augmentation therapymarket covered in this report is segmented –

1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza
2) By Route Of Administration: Oral; Injection; Inhalation
3) By End User: Hospitals; Specialty Clinics; Other End Users

Key Trends Driving Growth In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
Major companies operating in the acute respiratory distress syndrome (ARDS) market are focusing on developing innovative therapies, such as recombinant technology-based drug development, to sustain their position in the market. The recombinant DNA technology is used to manufacture therapeutic pharmaceuticals recombinant technology-based drug development. This method includes modifying the DNA of live organisms to synthesize specific proteins. For instance, in March 2022, Inhibrx Inc., a US-based biotechnology company, announced that INBRX-101 had received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating alpha-1 antitrypsin deficiency (AATD). INBRX-101 is a recombinant human AAT-Fc fusion protein with the potential for a once-monthly dosage. It is intended to safely achieve and maintain levels of AAT found in healthy individuals.

Key Player In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

View the full alpha-1 antitrypsin deficiency augmentation therapy market report here:
https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - Regional Insights:
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company